The DOI matches its Crossref record; 125 of the 125 references it cites were found in a registry or an index.
The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications
Abstract
Background: Hepatocellular carcinoma (HCC) is still a major health problem, often diagnosed at an advanced stage. The multikinase inhibitor sorafenib is to date the sole approved systemic therapy. Several signalling pathways are implicated in tumour development and progression. Among these pathways, the Ras/MAPK pathway is activated in 50–100% of human HCC s and is correlated with a poor prognosis. The aim of this work was to review the main intracellular mechanisms leading to aberrant Ras pathway activation in HCC and the potential therapeutic implications. Materials and methods: This review is based on the material found on PubMed up to December 2014. ‘Ras signaling, Ras dysregulation, Ras inhibition, MAPK pathway, cancer, hepatocarcinoma and liver cancer’ alone or in combination were the main terms used for online research. Results: Multiple mechanisms lead to the deregulation of the Ras pathway in liver cancer. Ras and Raf gene mutations are rare events in human hepatocarcinogenesis in contrast to experimental models in rodents. Downregulation of several Ras/MAPK pathway inhibitors such as GAP s, RASSF proteins, DUSP 1, Sprouty and Spred proteins is largely implicated in the aberrant activation of this pathway in the context of wild‐type Ras and Raf genes. Epigenetic or post‐transcriptional mechanisms lead to the downregulation of these tumour suppressor genes. Conclusion: Ras/MAPK pathway effectors may be considered as potential therapeutic targets in the field of HCC. In particular after the arrival of sorafenib, more Ras/MAPK inhibitors have emerged and are still in preclinical or clinical investigation for HCC therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis
El–Serag, H. B., & Rudolph, K. L. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.061 · Cited by 5,415
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
MAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019
Epithelial–mesenchymal transitions in development and pathologies
Thiery, J. P. (2003) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2003.10.006 · Cited by 1,704
Liu, L., Cao, Y., Chen, C., Zhang, X., McNabola, A., Wilkie, D., Wilhelm, S., Lynch, M., & Carter, C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1377 · Cited by 1,536
Wilhelm, S. M., Dumas, J., Adnane, L., Lynch, M., Carter, C. A., Schütz, G., Thierauch, K., & Zopf, D. (2011) · International Journal of Cancer · doi:10.1002/ijc.25864 · Cited by 1,355
Molecular targeted therapies in hepatocellular carcinoma†
Llovet, J. M., & Bruix, J. (2008) · Hepatology · doi:10.1002/hep.22506 · Cited by 1,004
Ras in Cancer and Developmental Diseases
Fernandez-Medarde, A., & Santos, E. (2011) · Genes & Cancer · doi:10.1177/1947601911411084 · Cited by 897
Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?
Vigil, D., Cherfils, J., Rossman, K. L., & Der, C. J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2960 · Cited by 819
Ubiquitous Activation of Ras and Jak/Stat Pathways in Human HCC
Calvisi, D. F., Ladu, S., Gorden, A., Farina, M., Conner, E. A., Lee, J., Factor, V. M., & Thorgeirsson, S. S. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.01.006 · Cited by 710
Ras history: The saga continues
Cox, A. D., & Der, C. J. (2010) · Small GTPases · doi:10.4161/sgtp.1.1.12178 · Cited by 706
Ras and TGFβ cooperatively regulate epithelial cell plasticity and metastasis
Janda, E., Lehmann, K., Killisch, I., Jechlinger, M., Herzig, M., Downward, J., Beug, H., & Grünert, S. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200109037 · Cited by 706
Hoshino, R., Chatani, Y., Yamori, T., Tsuruo, T., Oka, H., Yoshida, O., Shimada, Y., Ari-i, S., Wada, H., Fujimoto, J., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1202367 · Cited by 691
Focus on hepatocellular carcinoma
Bruix, J., Boix, L., Sala, M., & Llovet, J. M. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00058-3 · Cited by 570
The changing pattern of epidemiology in hepatocellular carcinoma
Nordenstedt, H., White, D. L., & El-Serag, H. B. (2010) · Digestive and Liver Disease · doi:10.1016/s1590-8658(10)60507-5 · Cited by 535
Chappell, W. H., Steelman, L. S., Long, J. M., Kempf, R. C., Abrams, S. L., Franklin, R. A., Bäsecke, J., Stivala, F., Donia, M., Fagone, P., et al. (2011) · Oncotarget · doi:10.18632/oncotarget.240 · Cited by 510
Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance
Aksamitiene, E., Kiyatkin, A., & Kholodenko, B. N. (2012) · Biochemical Society Transactions · doi:10.1042/bst20110609 · Cited by 479
Ras oncogenes and their downstream targets
Rajalingam, K., Schreck, R., Rapp, U. R., & Albert, Š. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2007.01.012 · Cited by 458
The dark side of Ras: regulation of apoptosis
Cox, A. D., & Der, C. J. (2003) · Oncogene · doi:10.1038/sj.onc.1207111 · Cited by 437
MAP kinases and the control of nuclear events
Turjanski, A. G., Vaqué, J. P., & Gutkind, J. S. (2007) · Oncogene · doi:10.1038/sj.onc.1210415 · Cited by 432
Calvisi, D. F., Ladu, S., Gorden, A., Farina, M., Lee, J.-S., Conner, E. A., Schroeder, I., Factor, V. M., & Thorgeirsson, S. S. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31457 · Cited by 393
Yeung, K., Janosch, P., McFerran, B., Rose, D. W., Mischak, H., Sedivy, J. M., & Kolch, W. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.9.3079-3085.2000 · Cited by 389
Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma
Tannapfel, A., Sommerer, F., Benicke, M., Katalinic, A., Uhlmann, D., Witzigmann, H., Hauss, J., & Wittekind, C. (2003) · Gut · doi:10.1136/gut.52.5.706 · Cited by 343
Ito, Y., Sasaki, Y., Horimoto, M., Wada, S., Tanaka, Y., Kasahara, A., Ueki, T., Hirano, T., Yamamoto, H., Fujimoto, J., et al. (1998) · Hepatology · doi:10.1002/hep.510270409 · Cited by 334
伊藤, 善. (1998) · doi:10.11501/3155565 · Cited by 300
Huynh, H., Nguyen, T. T. T., Chow, K.-H. K.-P., Tan, P. H., Soo, K. C., & Tran, E. (2003) · BMC Gastroenterology · doi:10.1186/1471-230x-3-19 · Cited by 289
MEK in cancer and cancer therapy
Neuzillet, C., Tijeras-Raballand, A., de Mestier, L., Cros, J., Faivre, S., & Raymond, E. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.10.001 · Cited by 264
From basic research to clinical development of MEK1/2 inhibitors for cancer therapy
Frémin, C., & Meloche, S. (2010) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-3-8 · Cited by 243
Cellular and molecular mechanisms of hepatocellular carcinoma: an update
Aravalli, R. N., Cressman, E. N. K., & Steer, C. J. (2013) · Archives of Toxicology · doi:10.1007/s00204-012-0931-2 · Cited by 225
Increased MAPK Expression and Activity in Primary Human Hepatocellular Carcinoma
Schmidt, C. M., McKillop, I. H., Cahill, P. A., & Sitzmann, J. V. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6840 · Cited by 212
Hepatocarcinogenesis in Mice with β-Catenin and Ha-Ras Gene Mutations
Harada, N., Oshima, H., Katoh, M., Tamai, Y., Oshima, M., & Taketo, M. M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2123 · Cited by 194
Predicting Hepatocellular Carcinoma by Detection of Aberrant Promoter Methylation in Serum DNA
Zhang, Y.-J., Wu, H.-C., Shen, J., Ahsan, H., Tsai, W. Y., Yang, H.-I., Wang, L.-Y., Chen, S.-Y., Chen, C.-J., & Santella, R. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1900 · Cited by 191
Lee, H. C., Tian, B., Sedivy, J. M., Wands, J. R., & Kim, M. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.07.012 · Cited by 190
Cancer gene discovery in hepatocellular carcinoma
Zender, L., Villanueva, A., Tovar, V., Sia, D., Chiang, D. Y., & Llovet, J. M. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2009.12.034 · Cited by 186
Gotzmann, J., Huber, H., Thallinger, C., Wolschek, M., Jansen, B., Schulte-Hermann, R., Beug, H., & Mikulits, W. (2002) · Journal of Cell Science · doi:10.1242/jcs.115.6.1189 · Cited by 185
Effects of hepatitis B virus X protein on the development of liver cancer
Zhang, X., Zhang, H., & Ye, L. (2006) · Journal of Laboratory and Clinical Medicine · doi:10.1016/j.lab.2005.10.003 · Cited by 181
Ras–effector interactions: after one decade
Herrmann, C. (2003) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(02)00007-6 · Cited by 179
Mitogen-activated protein kinases in hepatocellular carcinoma development
Min, L., He, B., & Hui, L. (2011) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2010.10.011 · Cited by 178
Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma
Schagdarsurengin, U., Wilkens, L., Steinemann, D., Flemming, P., Kreipe, H. H., Pfeifer, G. P., Schlegelberger, B., & Dammann, R. (2003) · Oncogene · doi:10.1038/sj.onc.1206338 · Cited by 176
Yu, J., Ni, M., Xu, J., Zhang, H., Gao, B., Gu, J., Chen, J., Zhang, L., Wu, M., Zhen, S., et al. (2002) · BMC Cancer · doi:10.1186/1471-2407-2-29 · Cited by 170
Targeted therapy for hepatocellular carcinoma: novel agents on the horizon
Cervello, M., McCubrey, J. A., Cusimano, A., Lampiasi, N., Azzolina, A., & Montalto, G. (2012) · Oncotarget · doi:10.18632/oncotarget.466 · Cited by 170
Yoshida, T., Hisamoto, T., Akiba, J., Koga, H., Nakamura, K., Tokunaga, Y., Hanada, S., Kumemura, H., Maeyama, M., Harada, M., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209635 · Cited by 169
An expanding role for RAS GTPase activating proteins (RAS GAPs) in cancer
Maertens, O., & Cichowski, K. (2014) · Advances in Biological Regulation · doi:10.1016/j.jbior.2014.04.002 · Cited by 167
Osaki, L., & Gama, P. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140510143 · Cited by 162
Buchmann, A., Bauer-Hofmann, R., Mahr, J., Drinkwater, N. R., Luz, A., & Schwarz, M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.3.911 · Cited by 159
Calvisi, D. F., Ladu, S., Conner, E. A., Seo, D., Hsieh, J.-T., Factor, V. M., & Thorgeirsson, S. S. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.06.036 · Cited by 159
Maronpot, R. R., Fox, T., Malarkey, D. E., & Goldsworthy, T. L. (1995) · Toxicology · doi:10.1016/0300-483x(95)03112-s · Cited by 153
O’Neil, B. H., Goff, L. W., Kauh, J. S. W., Strosberg, J., Bekaii‐Saab, T., Lee, R.-M., Kazi, A., Moore, D. T., Learoyd, M., Lush, R. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.9432 · Cited by 151
The developing story of Sprouty and cancer
Masoumi-Moghaddam, S., Amini, A., & Morris, D. L. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-014-9497-1 · Cited by 150
Fong, C. W., Chua, M., McKie, A. B., Ling, S. H. M., Mason, V., Li, R., Yusoff, P., Lo, T. L., Leung, H. Y., So, S. K., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1072 · Cited by 150
Huynh, H. T., Soo, K. C., Chow, P. K. H., & Tran, E. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0436 · Cited by 150
Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma*1
Hwang, Y. (2004) · Hepatology Research · doi:10.1016/j.hepres.2004.02.009 · Cited by 143
RASSF tumor suppressor gene family: Biological functions and regulation
Volodko, N. V., Gordon, M., Salla, M., Ghazaleh, H. A., & Baksh, S. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.02.041 · Cited by 137
Lin, Y., Chuang, S., & Yang, J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301854200 · Cited by 136
NORE1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers
Hesson, L. B., Dallol, A., Minna, J. D., Maher, E. R., & Latif, F. (2003) · Oncogene · doi:10.1038/sj.onc.1206191 · Cited by 130
Calvisi, D. F., Pinna, F., Meloni, F., Ladu, S., Pellegrino, R., Sini, M., Daino, L., Simile, M. M., Miglio, M. R. D., Virdis, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6157 · Cited by 130
Jin, H., Wang, X., Ying, J., Wong, A., Cui, Y., Srivastava, G., Shen, Z.-Y., Li, E., Zhang, Q., Jin, J., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700153104 · Cited by 127
Characterization of c-Ki-ras and N-ras oncogenes in aflatoxin B1-induced rat liver tumors.
McMahon, G., Davis, E. F., Huber, L. J., Kim, Y., & Wogan, G. N. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.3.1104 · Cited by 125
Gao, W., Kondo, Y., Shen, L., Shimizu, Y., Sano, T., Yamao, K., Natsume, A., Gotô, Y., Ito, M., Murakami, H., et al. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn170 · Cited by 122
Development of Hepatocellular Carcinoma in Iqgap2 -Deficient Mice Is IQGAP1 Dependent
Schmidt, V. A., Chiariello, C. S., Capilla, E., Miller, F. W., & Bahou, W. F. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01090-07 · Cited by 121
Interspecies comparison of liver carcinogenesis: implications for cancer risk assessment
Grisham, J. W. (1997) · Carcinogenesis · doi:10.1093/carcin/18.1.59 · Cited by 118
Deregulated Ras signaling in developmental disorders: new tricks for an old dog
Schubbert, S., Bollag, G. E., & Shannon, K. (2007) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2006.12.004 · Cited by 117
Lee, S. A., Ho, C., Roy, R., Kosinski, C., Patil, M. A., Tward, A. D., Fridlyand, J., & Chen, X. (2008) · Hepatology · doi:10.1002/hep.22169 · Cited by 114
Caja, L., Sancho, P., Bertrán, E., Iglesias‐Serret, D., Gil, J., & Fabregat, I. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1482 · Cited by 110
Epigenetic combination therapy as a tumor‐selective treatment approach for hepatocellular carcinoma
Venturelli, S., Armeanu, S., Pathil, A., Hsieh, C., Weiß, T. S., Vonthein, R., Wehrmann, M., Gregor, M., Lauer, U. M., & Bitzer, M. (2007) · Cancer · doi:10.1002/cncr.22652 · Cited by 105
Huynh, H. T., Ngo, V. C., Koong, H. N., Poon, D. Y. H., Choo, S. P., Toh, H. C., Thng, C. H., Chow, P. K. H., Ong, H. S., Chung, A. Y. F., et al. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.10.008 · Cited by 103
Frémin, C., Ezan, F., Boisselier, P., Bessard, A., Pagès, G., Pouysségur, J., & Baffet, G. (2007) · Hepatology · doi:10.1002/hep.21551 · Cited by 99
Wang, C., Cigliano, A., Delogu, S., Armbruster, J., Dombrowski, F., Evert, M., Chen, X., & Calvisi, D. F. (2013) · Cell Cycle · doi:10.4161/cc.25099 · Cited by 96
Molecular approaches to treatment of hepatocellular carcinoma
Lachenmayer, A., Alsinet, C., Chang, C., & Llovet, J. M. (2010) · Digestive and Liver Disease · doi:10.1016/s1590-8658(10)60515-4 · Cited by 94
Molecular targeted therapy for hepatocellular carcinoma: Current and future
Shin, J. W. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i37.6144 · Cited by 91
Raf kinase inhibitor protein is downregulated in hepatocellular carcinoma
Schuierer, M. M., Bataille, F., Weiß, T. S., Hellerbrand, C., & Bosserhoff, A. (2006) · Oncology Reports · doi:10.3892/or.16.3.451 · Cited by 86
Colombino, M., Sperlongano, P., Izzo, F., Tatangelo, F., Botti, G., Lombardi, A., Accardo, M., Tarantino, L., Sordelli, I., Agresti, M., et al. (2012) · Cell Death and Disease · doi:10.1038/cddis.2011.136 · Cited by 81
RNAi-mediated ERK2 knockdown inhibits growth of tumor cells in vitro and in vivo
Bessard, A., Frémin, C., Ezan, F., Fautrel, A., Gailhouste, L., & Baffet, G. (2008) · Oncogene · doi:10.1038/onc.2008.163 · Cited by 81
McKillop, I. H., Schmidt, C. M., Cahill, P. A., & Sitzmann, J. V. (1997) · Hepatology · doi:10.1002/hep.510260615 · Cited by 81
Targeted therapy of hepatocellular carcinoma: Present and future
Chan, S. L., & Yeo, W. (2012) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2012.07096.x · Cited by 79
Tsuboi, Y., Ichida, T., Sugitani, S., Genda, T., Inayoshi, J., Takamura, M., Matsuda, Y., Nomoto, M., & Aoyagi, Y. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.0940.x · Cited by 77
Weihrauch, M., Benicke, M., Lehnert, G., Wittekind, C., Wrbitzky, R., & Tannapfel, A. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1675 · Cited by 77
IQGAP1 and IQGAP2 are Reciprocally Altered in Hepatocellular Carcinoma
White, C. D., Khurana, H., Gnatenko, D. V., Li, Z., Odze, R. D., Sacks, D. B., & Schmidt, V. A. (2010) · BMC Gastroenterology · doi:10.1186/1471-230x-10-125 · Cited by 77
Chen, L., Shi, Y., Jiang, C., Wei, L., Wang, Y.-L., & Dai, G. (2011) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2011.01.023 · Cited by 74
Carr, B. I., Cavallini, A., Lippolis, C., D’Alessandro, R., Messa, C., Refolo, M. G., & Tafaro, A. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.24148 · Cited by 74
The Effects of a Novel MEK Inhibitor PD184161 on MEK-ERK Signaling and Growth in Human Liver Cancer
Klein, P. J., Schmidt, C. M., Wiesenauer, C. A., Choi, J. N., Gage, E. A., Yip-Schneider, M., Wiebke, E. A., Wang, Y., Omer, C. A., & Sebolt, J. S. (2006) · Neoplasia · doi:10.1593/neo.05373 · Cited by 73
Hu, L., Chen, G., Yu, H., et al. (2010) · Hepatology International · doi:10.1007/s12072-010-9164-8 · Cited by 71
Clinical Trials in Hepatocellular Carcinoma: An Update
Shen, Y., Lin, Z., Hsu, C., Hsu, C., Shao, Y., & Cheng, A. (2013) · Liver Cancer · doi:10.1159/000343850 · Cited by 69
Zucchini-Pascal, N., Peyre, L., & Rahmani, R. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141020768 · Cited by 67
Quantitative evaluation of RASSF1Amethylation in the non-lesional, regenerative and neoplastic liver
Gioia, S. D., Bianchi, P. P., Destro, A., Grizzi, F., Malesci, A., Laghi, L., Levrero, M., Morabito, A., & Roncalli, M. G. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-89 · Cited by 65
Overexpression of Tiam1 in hepatocellular carcinomas predicts poor prognosis of HCC patients
Ding, Y., Chen, B., Wang, S., Zhao, L., Chen, J., Ding, Y., Chen, L., & Luo, R. (2008) · International Journal of Cancer · doi:10.1002/ijc.23954 · Cited by 64
Expression and subcellular localization of Spred proteins in mouse and human tissues
Engelhardt, C. M., Bundschu, K., Messerschmitt, M., Renné, T., Walter, U., Reinhard, M., & Schuh, K. (2004) · Histochemistry and Cell Biology · doi:10.1007/s00418-004-0725-6 · Cited by 64
Recent progress in the identification of BRAF inhibitors as anti-cancer agents
El‐Nassan, H. B. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.11.018 · Cited by 62
Lee, S. A., Ladu, S., Evert, M., Dombrowski, F., Murtas, V. D., Chen, X., & Calvisi, D. F. (2010) · Hepatology · doi:10.1002/hep.23681 · Cited by 60
Wang, C., Delogu, S., Ho, C., Lee, S. A., Gui, B., Jiang, L., Ladu, S., Cigliano, A., Dombrowski, F., Evert, M., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.04.026 · Cited by 56
The MAPK MEK1/2-ERK1/2 Pathway and Its Implication in Hepatocyte Cell Cycle Control
Guégan, J.-P., Frémin, C., & Baffet, G. (2012) · International Journal of Hepatology · doi:10.1155/2012/328372 · Cited by 56
Moshnikova, A., Frye, J., Shay, J. W., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m511837200 · Cited by 55
Qiu, G., Xie, H., Wheelhouse, N., Harrison, D. J., Chen, G. G., Salto‐Tellez, M., Lai, P. B. S., Ross, J. A., & Hooi, S. C. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.11.012 · Cited by 55
Schmieder, R., Puehler, F., Neuhaus, R., Kissel, M., Adjei, A. A., Miner, J. N., Mumberg, D., Ziegelbauer, K. B., & Scholz, A. (2013) · Neoplasia · doi:10.1593/neo.13812 · Cited by 53
Huynh, H. T., Chow, P. K. H., & Soo, K. C. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0162 · Cited by 50
RalA signaling pathway as a therapeutic target in hepatocellular carcinoma (HCC)
Ezzeldin, M., Borrego-Diaz, E., Taha, M., Esfandyari, T., Wise, A. L., Peng, W., Rouyanian, A., Kermani, A. A., Soleimani, M., Patrad, E., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.03.020 · Cited by 48
Charette, N., Saeger, C. D., Lannoy, V., Horsmans, Y., Leclercq, I. A., & Stärkel, P. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-256 · Cited by 48
Self-citationMolecular Therapies in Hepatocellular Carcinoma: What Can We Target?
Galuppo, R., Ramaiah, D., Ponte, O. M., & Gedaly, R. (2014) · Digestive Diseases and Sciences · doi:10.1007/s10620-014-3058-x · Cited by 47
Genetic and Epigenetic Control of Molecular Alterations in Hepatocellular Carcinoma
Feo, F., Frau, M., Tomasi, M. L., Brozzetti, S., & Pascale, R. M. (2009) · Experimental Biology and Medicine · doi:10.3181/0901-mr-40 · Cited by 47
Dysregulated serum response factor triggers formation of hepatocellular carcinoma
Ohrnberger, S., Thavamani, A., Braeuning, A., Lipka, D. B., Kirilov, M., Geffers, R., Authenrieth, S. E., Römer, M., Zell, A., von Bonin, M., et al. (2014) · Hepatology · doi:10.1002/hep.27539 · Cited by 44
B-Raf and Ha-ras mutations in chemically induced mouse liver tumors
Jaworski, M., Buchmann, A., Bauer, P. O., Rieß, O., & Schwarz, M. (2004) · Oncogene · doi:10.1038/sj.onc.1208265 · Cited by 43
Tiam1 is associated with hepatocellular carcinoma metastasis
Huang, J., Ye, X., Guan, J., Chen, B., Li, Q., Zheng, X., Liu, L., Wang, S., Ding, Y., Ding, Y., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27627 · Cited by 42
Honma, N., Genda, T., Matsuda, Y., Yamagiwa, S., Takamura, M., Ichida, T., & Aoyagi, Y. (2006) · Laboratory Investigation · doi:10.1038/labinvest.3700427 · Cited by 41
Calvisi, D. F., Pinna, F., Pellegrino, R., Sanna, V., Sini, M., Daino, L., Simile, M. M., Miglio, M. R. D., Frau, M., Tomasi, M. L., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23720 · Cited by 40
RASSF1A-Mediated Regulation of AREG via the Hippo Pathway in Hepatocellular Carcinoma
Ahn, E. Y., Kim, J. S., Kim, G. J., & Park, Y. N. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0665 · Cited by 39
Differential expression of sprouty genes in hepatocellular carcinoma
Sirivatanauksorn, Y., Sirivatanauksorn, V., Srisawat, C., Khongmanee, A., & Tongkham, C. (2011) · Journal of Surgical Oncology · doi:10.1002/jso.22095 · Cited by 38
Gailhouste, L., Ezan, F., Bessard, A., Frémin, C., Rageul, J., Langouët, S., & Baffet, G. (2009) · International Journal of Cancer · doi:10.1002/ijc.24950 · Cited by 38
Huynh, H. T. (2010) · Cancer · doi:10.1002/cncr.24863 · Cited by 38
Upregulation of DNMT1 mediated by HBx suppresses RASSF1A expression independent of DNA methylation
Qiu, X., Zhang, L., Lu, S., Song, Y., LAO, Y., Hu, J., & Fan, H. (2013) · Oncology Reports · doi:10.3892/or.2013.2848 · Cited by 36
A rare point mutation in the Ras oncogene in hepatocellular carcinoma
Taketomi, A., Shirabe, K., Muto, J., Yoshiya, S., Motomura, T., Mano, Y., Ikegami, T., Yoshizumi, T., Sugio, K., & Maehara, Y. (2012) · Surgery Today · doi:10.1007/s00595-012-0462-8 · Cited by 31
Regorafenib: an evidence-based review of its potential in patients with advanced liver cancer
Singal, A. K., & Ravi, S. (2014) · Core evidence · doi:10.2147/ce.s48626 · Cited by 30
Buchmann, A., Karcier, Z., Schmid, B., Strathmann, J., & Schwarz, M. (2007) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2007.08.015 · Cited by 29
Ma, X.-N., Liu, X., Yang, Y., Xiao, F., Li, Q., Yan, J., Zhang, Q., Wang, L., Li, X., & Wang, H. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.06.068 · Cited by 29
Calvisi, D. F., Evert, M., & Dombrowski, F. (2012) · Molecular Biology International · doi:10.1155/2012/849874 · Cited by 17
Reversibility of regorafenib effects in hepatocellular carcinoma cells
D’Alessandro, R., Refolo, M. G., Lippolis, C., Messa, C., Cavallini, A., Rossi, R., Resta, L., Carlo, A. D., & Carr, B. I. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2269-8 · Cited by 15
Schneider‐Merck, T., Borbath, I., Charette, N., Saeger, C. D., Abarca, J., Leclercq, I. A., Horsmans, Y., & Stärkel, P. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.04.014 · Cited by 15
Self-citationSprouty keeps bowel kinases regular in colon cancer, while miR-21 targets Sprouty
Frey, M. R., Carraro, G., Batra, R. K., Polk, D. B., & Warburton, D. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.1.14176 · Cited by 13
Ras in digestive oncology: from molecular biology to clinical implications
Charette, N., Vandeputte, C., & Stärkel, P. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000088 · Cited by 13
Self-citationStärkel, P., Charette, N., Borbath, I., Schneider‐Merck, T., Saeger, C. D., Abarca, J., Leclercq, I. A., & Horsmans, Y. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.20849 · Cited by 10
Self-citationGrowth factor transduction pathways: paradigm of anti-neoplastic targeted therapy
Carlomagno, F., & Chiariello, M. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1177-7 · Cited by 6
Cited by
From NASH to HCC: current concepts and future challenges
Anstee, Q. M., Reeves, H. L., Kotsiliti, E., Govaere, O., & Heikenwalder, M. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0145-7 · Cited by 1,392
Hepatocellular carcinoma: signaling pathways and therapeutic advances
Zheng, J., Wang, S., Xia, L., Sun, Z., Chan, K. M., Bernards, R., Qin, W., Chen, J., Xia, Q., & Jin, H. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02075-w · Cited by 341
MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma
Moon, H., & Ro, S. W. (2021) · Cancers · doi:10.3390/cancers13123026 · Cited by 326
Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches
Liu, F., Chen, J., Li, K., Li, H., Zhu, Y., Zhai, Y., Lu, B., Fan, Y., Liu, Z., Chen, X., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02046-3 · Cited by 326
Current and Future Treatment of Hepatocellular Carcinoma: An Updated Comprehensive Review
Daher, S., Massarwa, M., Benson, A. A., & Khoury, T. (2018) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2017.00031 · Cited by 304
Metadata
- Authors
- Delire, B., & Stärkel, P.
- Venue
- European Journal of Clinical Investigation
- Publisher
- Wiley
- Published
- 2015-05-11
- Volume
- 45
- Issue
- 6
- Pages
- 609-623
- ISSN
- 0014-2972 (ISSN-L)
- 1365-2362
- OpenAlex
- W1997769423
- Cited by
- 275
- References
- 125
- FWCI
- 6.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.